Critical Therapeutics to Announce Fourth-Quarter and Year-End 2005 Financial Results on February 9, 2006.LEXINGTON, Mass. -- Critical Therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. , Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : CRTX), a biopharmaceutical company engaged in the discovery, development and commercialization of products for respiratory, inflammatory and critical care diseases, will conduct a conference call at 5:00 p.m. ET Thursday, February 9, following the after-market release of its fourth-quarter and year-end 2005 financial results. Critical Therapeutics President and Chief Executive Officer Paul Rubin, M.D. will lead the call, during which senior management will discuss the Company's fourth-quarter financial results, additional corporate activities and upcoming milestones. Investors and others are invited to listen live via telephone or the Internet Internet Publicly accessible computer network connecting many smaller networks from around the world. It grew out of a U.S. Defense Department program called ARPANET (Advanced Research Projects Agency Network), established in 1969 with connections between computers at the .
What: Critical Therapeutics Fourth-Quarter and Year-End 2005
Financial Results Conference Call
When: 5:00 p.m. ET Thursday, February 9, 2006
Dial-in: From the U.S. and Canada, dial (888) 349-5690
International callers, dial (706) 643-3945
Conference
ID: 4108103
Webcast: Visit www.crtx.com, go to the "Investors" page and then
click on the conference call link about five minutes
before the call.
To access the replay, visit www.crtx.com, click on "Investors" and then on "Webcasts & Presentations." About Critical Therapeutics Critical Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of products for respiratory, inflammatory and critical care diseases. The Company owns worldwide rights to ZYFLO Zileuton (Zyflo) A medication that interferes with the biosynthetic pathway that produces leukotrienes; used to help prevent asthma attacks. Mentioned in: Leukotriene Inhibitors Zyflo® Zileuton, see there (R) (zileuton zileuton /zi·leu·ton/ (zi-loo´ton) an inhibitor of leukotriene formation, used as an antiasthmatic. Zileuton (Zyflo) tablets), as well as other formulations of zileuton. ZYFLO is the only 5-lipoxygenase inhibitor inhibitor /in·hib·i·tor/ (in-hib´i-tor) 1. any substance that interferes with a chemical reaction, growth, or other biologic activity. 2. approved for marketing by the U.S. Food and Drug Administration. The Company's commercialization efforts for ZYFLO are carried out by its 80-person specialty sales force. Critical Therapeutics also is developing treatments directed toward the severe inflammatory response in acute diseases and conditions that lead to admission to the emergency room or intensive care unit, and acute exacerbations of other chronic diseases that frequently lead to hospitalization hospitalization /hos·pi·tal·iza·tion/ (hos?pi-t'l-i-za´shun) 1. the placing of a patient in a hospital for treatment. 2. the term of confinement in a hospital. . For more information, please visit www.crtx.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion